Piper Sandler's Thoughts on NewAmsterdam Pharma Co NV (NAMS) Post Investor Dinner

May 12, 2026 8:11 AM EDT Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $60.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login